BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3396 related articles for article (PubMed ID: 7642226)

  • 21. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O; Dohlsten M; Sjögren HO
    Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes.
    Tamada K; Harada M; Abe K; Li T; Tada H; Onoe Y; Nomoto K
    J Immunol; 1997 May; 158(10):4846-54. PubMed ID: 9144500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The augmenting effect of OK432-stimulated B cells on the in vitro generation of anti-tumor cytotoxic T lymphocytes from tumor-draining lymph node cells: the possible role of interleukin-12.
    Shinomiya Y; Harada M; Tamada K; Kurosawa S; Okamoto T; Terao H; Takenoyama M; Ito O; Hirashima C; Li T; Shirakusa T; Nomoto K
    In Vivo; 1997; 11(1):1-8. PubMed ID: 9067765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities.
    Stitz L; Baenziger J; Pircher H; Hengartner H; Zinkernagel RM
    J Immunol; 1986 Jun; 136(12):4674-80. PubMed ID: 3486908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of natural killer and T-cells in interferon induced inhibition of spontaneous metastases of the B16F10L murine melanoma.
    Markovic SN; Murasko DM
    Cancer Res; 1991 Feb; 51(4):1124-8. PubMed ID: 1705166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role.
    Schneeberger A; Koszik F; Schmidt W; Kutil R; Stingl G
    J Immunol; 1999 Jun; 162(11):6650-7. PubMed ID: 10352282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-gamma genes.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):191-201. PubMed ID: 7905286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local and systemic immune response to inactivated Candida albicans in mice.
    Scaringi L; Rosati E; Cornacchione P; Fettucciari K; Sabatini R; Biondi R; Mezzasoma L; Valiani M; D'Errico P; Marconi P
    Nat Immun; 1995 Sep; 14(5-6):234-49. PubMed ID: 8933818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of cellular anti-tumour responses by tumour-specific T suppressor lymphocytes.
    Haubeck HD; Stutenkemper R; Kölsch E
    Clin Exp Immunol; 1988 Oct; 74(1):47-52. PubMed ID: 2975538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
    Hinuma S; Naruo K; Shiho O; Tsukamoto K
    Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of mouse liver natural killer cells and NK1.1(+) T cells by bacterial superantigen-primed Kupffer cells.
    Dobashi H; Seki S; Habu Y; Ohkawa T; Takeshita S; Hiraide H; Sekine I
    Hepatology; 1999 Aug; 30(2):430-6. PubMed ID: 10421651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
    Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
    Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of NK1+ T cells and their IFN-gamma production in the generalized Shwartzman reaction.
    Ogasawara K; Takeda K; Hashimoto W; Satoh M; Okuyama R; Yanai N; Obinata M; Kumagai K; Takada H; Hiraide H; Seki S
    J Immunol; 1998 Apr; 160(7):3522-7. PubMed ID: 9531314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.
    Hájková R; Indrová M; Jandlová T; Bubeník J; Reinis M
    Folia Biol (Praha); 1999; 45(6):227-31. PubMed ID: 10732718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
    Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
    Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of innate immune cells in protection against Toxoplasma gondii at inflamed site.
    Nakano Y; Hisaeda H; Sakai T; Zhang M; Maekawa Y; Zhang T; Himeno K
    J Med Invest; 2001 Feb; 48(1-2):73-80. PubMed ID: 11286020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 170.